SignaBlok’s TREM-1 nanotherapy accepted by the Nanotechnology Characterization Laboratory (NCL, Frederick, Maryland) into its Assay Cascade characterization and testing program as one of the most promising cancer nanomedicine candidates.
SignaBlok awarded NIAMS / NIH SBIR Fast-Track grant to develop first-in-class TREM-1 inhibitor for treatment of rheumatoid arthritis
SignaBlok awarded DoD SBIR Phase I contract to support new technology to prevent the effects of acute radiation syndrome
SignaBlok attended the COVID-19 Virtual Partnering event and presented company’s approach to treatment of acute respiratory distress syndrome (ARDS), a major complication in severe cases of COVID-19
SignaBlok pitched on company’s standalone and combination immuno-oncology therapy at the 2019 Life Sciences Summit
SignaBlok wins NCI / NIH SBIR Phase II grant to test first-in-class TREM-1 inhibitor in combination with chemo- and immunotherapy for treatment of pancreatic cancer
SignaBlok selected as a RESI Pitch Challenge finalist to pitch on company’s oncology program at the 2019 Redefining Early Stage Investments (RESI) Conference
SignaBlok presented data on preclinical antitumor activity of a first-in-class TREM-1 inhibitory peptide GF9 as monotherapy and in combo with chemotherapy or radiation at the 2019 AACR Annual Meeting
SignaBlok presented preclinical data supporting efficacy of ligand-independent TREM-1 inhibitor in ameliorating alcoholic liver disease at the Liver Meeting 2018: American Association for the Study of Liver Diseases (AASLD)
